What is ON Diagnostics?
ON Diagnostics specializes in Biomechanical Computed Tomography (BCT) analysis, a cutting-edge approach to osteoporosis diagnosis. The company's VirtuOst service provides detailed measurements of bone mineral density and strength by analyzing existing CT scans of the hip or spine, thereby avoiding additional radiation exposure for patients. This innovative solution offers a cost-effective assessment of bone quality and fracture risk, delivering clinically impactful bone information to physicians to optimize patient treatment. ON Diagnostics also engages with patients who have undergone relevant CT scans and collaborates with researchers to deepen the understanding of bone strength through clinical trials.
How much funding has ON Diagnostics raised?
ON Diagnostics has raised a total of $143K across 1 funding round:
Debt
$143K
Debt (2021): $143K with participation from PPP
Key Investors in ON Diagnostics
PPP
Public-Private Partnership
What's next for ON Diagnostics?
With a large-scale, late-stage funding context, ON Diagnostics is poised for significant expansion and market penetration. The recent strategic investment likely signals confidence from investors in the company's technology and its potential to disrupt the osteoporosis diagnostics market. Future developments may include scaling up operations, enhancing the VirtuOst service with advanced AI capabilities, expanding its physician and patient outreach, and forging new research partnerships to further validate and advance bone strength assessment methodologies. The company's trajectory suggests a focus on solidifying its position as a leader in non-invasive bone health diagnostics.
See full ON Diagnostics company page
